AZN Latest Headlines

Top global stories this week; markets rally on rate-cut optimism

at seekingalpha.com (Sun, 5-Jul 1:45 PM)

AstraZeneca and Abbisko Partner on First-in-Class Oral PD-L1 Therapy to Address Unmet Needs in EGFR-Mutated NSCLC

Market Chameleon (Thu, 2-Jul 7:29 AM)

AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC

at seekingalpha.com (Thu, 2-Jul 8:02 AM)

AstraZeneca, Abbisko partner on lung cancer combination therapy trial

at seekingalpha.com (Thu, 2-Jul 12:33 AM)

AstraZeneca Completes Early AZD9829 Trial in CD123+ Blood Cancers: What Investors Should Watch

at www.tipranks.com (Wed, 1-Jul 12:30 PM)

AstraZeneca Adds 14,784 Shares Under Employee Schemes on LSE Main Market

at www.tipranks.com (Wed, 1-Jul 10:07 AM)

AstraZeneca Confirms Total Voting Rights at 1.55 Billion Shares

at www.tipranks.com (Wed, 1-Jul 10:04 AM)

Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)

at www.tipranks.com (Wed, 1-Jul 2:55 AM)

Anthropic Launches Claude Science AI Tool to Upend Lab and Pharma Research

at www.tipranks.com (Tue, 30-Jun 4:05 PM)

AstraZeneca’s ASCERTAIN Trial Wrap-Up: What Prostate Cancer Data Could Mean for AZN Investors

at www.tipranks.com (Tue, 30-Jun 12:30 PM)

AstraZeneca: Buy Rating Reiterated on Robust Pipeline Upside and Solid Execution; Price Target Unchanged at 16,500 GBp

at www.tipranks.com (Tue, 30-Jun 6:46 AM)

Deutsche Bank Remains a Sell on AstraZeneca (AZN)

at www.tipranks.com (Tue, 30-Jun 5:15 AM)

AstraZeneca (AZN) Receives a Buy from Barclays

at www.tipranks.com (Tue, 30-Jun 1:55 AM)

FDA Approval of BAXFENDY Sets New Benchmark in Hypertension Treatment—AstraZeneca’s Latest Win Offers Hope for 23 Million US Patients

Market Chameleon (Mon, 18-May 9:21 AM)

FDA Panel Endorses TRUQAP for PTEN-Deficient Prostate Cancer After Phase III Trial Shows 19% Risk Reduction in Progression

Market Chameleon (Fri, 1-May 7:33 AM)

AstraZeneca Delivers Strong Q1 2026 Driven by Oncology Growth and Robust Pipeline Readouts

Market Chameleon (Wed, 29-Apr 7:12 AM)

Tozorakimab Achieves Key Phase III Goal, Offering Hope for COPD Patients Resistant to Standard Therapies

Market Chameleon (Mon, 20-Apr 7:31 AM)